中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

22 records (took 0.024 seconds)

    DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
    11.
    发明申请
    DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER 审中-公开

    公开(公告)号：US20200157635A1

    公开(公告)日：2020-05-21

    申请号：US16591813

    申请日：2019-10-03

    Applicant: Genentech, Inc.

    Inventor： Marcin KOWANETZ ,  Mahrukh HUSENI ,  Wei ZOU

    IPC: C12Q1/6886 ,  G01N33/50 ,  C07K16/28

    Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention is based, at least in part, on the discovery that an immune-score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)).

    THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
    15.
    发明申请
    THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER 有权

    公开(公告)号：US20220412981A1

    公开(公告)日：2022-12-29

    申请号：US17686565

    申请日：2022-03-04

    Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

    Inventor： David FABRIZIO ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Marcin KOWANETZ ,  David SHAMES ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY ,  Wei ZOU

    IPC: G01N33/574 ,  C07K16/28 ,  C12Q1/6886 ,  A61P35/04 ,  A61P35/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705

    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

    THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
    18.
    发明申请
    THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER 审中-公开

    公开(公告)号：US20200031936A1

    公开(公告)日：2020-01-30

    申请号：US16655495

    申请日：2019-10-17

    Applicant: Genentech, Inc.

    Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

    IPC: C07K16/28 ,  C12Q1/6886 ,  G01N33/574

    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

Patent Agency Ranking